Premium
Randomized Double Masked Trial of Zhi Byed 11 , a Tibetan Traditional Medicine, Versus Misoprostol to Prevent Postpartum Hemorrhage in Lhasa, Tibet
Author(s) -
Miller Suellen,
Tudor Carrie,
Thorsten Vanessa,
Quzong Karma,
Dekyi Tsering,
Hartwell Ty,
Wright Linda L.,
Varner Michael W.
Publication year - 2009
Publication title -
journal of midwifery and women's health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.543
H-Index - 62
eISSN - 1542-2011
pISSN - 1526-9523
DOI - 10.1016/j.jmwh.2008.09.010
Subject(s) - misoprostol , uterotonic , medicine , randomized controlled trial , blood loss , obstetrics , incidence (geometry) , pregnancy , oxytocin , surgery , abortion , genetics , physics , optics , biology
The objective of this study was to compare a Tibetan traditional medicine (the uterotonic Zhi Byed 11 [ ZB11 ]) to oral misoprostol for prophylaxis of postpartum hemorrhage (PPH). We conducted a double‐blind randomized controlled trial at three hospitals in Lhasa, Tibet, People's Republic of China. Women (N = 967) were randomized to either ZB11 or misoprostol groups. Postpartum blood loss was measured in a calibrated blood collection drape. The primary combined outcome was incidence of PPH, defined as measured blood loss (MBL) ≥ 500 mL, administration of open label uterotonics, or maternal death. We found that the rate of the combined outcome was lower among the misoprostol group (16.1% versus 21.8% for ZB11; P = .02). Frequency of PPH was lower with misoprostol (12.4% versus 17.4%; P = .02). There were no significant differences in MBL > 1000 mL or mean or median MBL. Fever was significantly more common in the misoprostol group ( P = .03). The rate of combined outcome was significantly lower among women receiving misoprostol. However, other indices of obstetric hemorrhage were not significantly different.